Serina Therapeutics CEO to Present at Innovation Conference

Serina Therapeutics ( (SER) ) has provided an update.

On April 7, 2025, Serina Therapeutics announced that its CEO, Steve Ledger, will present at the Jones Healthcare and Technology Innovation Conference on April 9, 2025. The presentation will highlight the company’s advancements, particularly the POZ Platform and the upcoming clinical trial of SER-252 for Parkinson’s disease. This announcement underscores Serina’s strategic positioning in the biotechnology sector and its potential impact on treatment options for Parkinson’s disease, with SER-252 projected to achieve significant market success.

Spark’s Take on SER Stock

According to Spark, TipRanks’ AI Analyst, (SER) is a Neutral.

Serina Therapeutics’ stock score is primarily hindered by its severe financial challenges, including declining revenue, high liabilities, and negative cash flow. While there is some short-term technical momentum, the overall valuation is weak due to negative earnings. Positive corporate developments and strategic initiatives are noted but do not offset the fundamental financial concerns.

To see Spark’s full report on (SER) stock, click here.

More about Serina Therapeutics

Serina Therapeutics is a biotechnology company specializing in drug optimization technology for multiple modalities, including small molecules, RNA, and antibody-drug conjugates (ADCs). The company is known for its POZ Platform, which enhances drug delivery and efficacy, and has partnered with Pfizer in the RNA vaccine field. Serina’s lead program, SER-252, is a novel treatment for advanced Parkinson’s disease, expected to enter clinical trials in the fourth quarter of 2025.

YTD Price Performance: 2.94%

Average Trading Volume: 12,802

Technical Sentiment Signal: Strong Buy

Current Market Cap: $52.14M

Learn more about SER stock on TipRanks’ Stock Analysis page.